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Abstract: Fibrosis of adipose tissue (AT) increases AT rigidity, reduces its expandability and
contributes to metabolic dysfunction. Collagen type VI, alpha3 (COL6A3) encodes one
subunit of a fibrotic extracellular matrix (ECM) protein highly expressed in rodent AT.
Knock-out of collagen VI in rodent AT led to a significant improvement in metabolic
health in obese, diabetic (ob/ob) mice however, it is unknown whether this collagen
has the same metabolic significance in human AT.  We therefore aimed to undertake a
comprehensive assessment of COL6A3 in relation to human AT and obesity.
Characterisation of COL6A3 in human AT showed 5fold higher expression in the
stromalvascular fraction compared with adipocyte expression and significantly higher
expression in subcutaneous than omental AT.  In both depots COL6A3 expression
appeared to be lowered in obesity, whilst diet and surgery-induced weight loss
increased COL6A3 expression in subcutaneous AT and serum. Leptin treatment
caused a dose dependent decrease in COL6A3 expression although no effect was
seen with insulin or glucose treatment and no difference observed in subjects with
diabetes.  In addition, we found that the collagen expression profile in humans differs
significantly from rodents as COL6A3 does not appear to be the predominant collagen
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in adipose, muscle or liver. Our findings oppose those initially seen in rodent studies
and most importantly, demonstrate a direct regulation of COL6A3 by leptin.  This
highlights the importance of a paracrine leptin signalling pathway in human AT and
suggests an additional mechanism by which leptin can regulate ECM composition and
with it AT expandability.
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Dear Professor Gore,  
Re: McCulloch et al. “COL6A3 is regulated by leptin in human adipose tissue and reduced in obesity”  
Thank you for giving us the opportunity to resubmit this manuscript. Additional data show that the 
increase of adipose tissue COL6A3 following bariatric surgery is due to its induction by 
stromalvascular cells and not adipocytes. As advised by the peer reviewer, we set up experiments to 
study the signal pathways by which leptin regulates COL6A3 in mouse cell lines. This showed that 
COL6A3 is not regulated by leptin in mouse adipocytes and is in keeping with the influence of SVF in 
COL6A3 regulation.  We now feel that the manuscript has been considerably improved by this 
additional work, and we thank you and the peer reviewers for your suggestions for improving the 
manuscript. With your agreement this paper may be the first to show that higher COL6A3 in humans 
is not adversely linked to obesity or diabetes. This is unexpected and contradicts previous findings 
which sparked an interest in the potential role of collagens in human diabetes with the example of 
COL6A3. 
We declare that this manuscript is original, has not been published before and is not currently being 
considered for publication elsewhere.  We wish to confirm that there are no known conflicts of 
interest associated with this publication and there has been no significant financial support for this 
work which would have influenced its outcome.  The manuscript has been read and approved by all 
named authors including the new collaborators. 
We hope you find our manuscript suitable for publication and we look forward to hearing from you 
at your earliest convenience. 
Yours sincerely, 
 
Dr Katarina Kos 
Senior Lecturer 
University of Exeter 
Cover Letter
Reviewer #1 
 
1. We would like to thank the reviewers for their positive comments and recognising the novelty of our 
data.  
The reviewer noted contradicting expression levels in the group of women with and without bariatric 
surgery: “as an example, in page 12, it is stated that COL6A3 expression was 1.2 ± 0.1 AU in 
subcutaneous adipose tissue in the cohort of healthy female subjects (whether lean or obese, it is not 
stated, but their BMI should be comprised between 22.5-28.4-33.7, according to that depicted in page 
7), while in the cohort of subjects undergoing bariatric surgery (BMI: 44.4±7.3, Table 1; mostly women), 
the expression levels were 2.0±02 AU”. 
 
An apparent contradiction in subcutaneous expression levels has been noted between healthy subjects and 
those undergoing bariatric surgery.  However, we would like to draw the reviewer’s attention to the fact 
that these two expression analyses were performed independently and therefore cannot be directly 
compared.  We utilise the 2
^-ΔΔCT
method of analysis, in which expression of individual genes are made 
relative to an arbitrary value within that probe set, i.e. Ct of the most highly expressed sample. This value 
will inevitably change between experiments due to the utilisation of unique samples, and the variance in 
this calibrator sample is the reason behind the varying expression levels (given in Arbitrary Units).  On this 
basis we are only able to compare samples run during a single experiment, not between experiments. 
 
2. The reviewer points out that the analysis are mainly based on mRNA expression data suggesting that at 
least a group of samples could be employed for such an analysis. The method employed for RNA 
isolation in most of the studies (Tri reagent) enables the simultaneous isolation of proteins and, though 
not of the best quality, these could be employed for western blot analysis.  
We are aware of the limitations regarding the use of mRNA in isolation without protein analysis.  To 
overcome this we have previously attempted to isolate proteins from the organic phase of TRI reagent, 
however in our hands this has been of little success.  As the reviewer points out, the protein obtained from 
TRI reagent is not of the best quality.  Coomassie staining of proteins from multiple samples demonstrated 
non-uniform extraction from adipose tissue.  As we want to compare directly between our samples we feel 
it would be inappropriate to use these TRI reagent extracted proteins as we are likely to identify false 
positives or negatives due to the variance in protein extraction. We included Immunohistology and serum 
protein analyses. 
 
 
3. The reviewer suggests protein analyses, e.g. by Western and Tri reagent and/or immunohistological 
staining and suggests that it could be that, in spite of the minor decrease in COL6A3 expression levels, 
COL6A3 protein content undergoes more important changes under the different conditions examined 
due to, for instance, increased translation efficiency, and/or decreased protein turnover.     
 
We have included an additional figure (Figure 4 B-D) to show the immunostaining for COL6A3 in omental 
adipose tissue. Sufficient tissue was not available to perform a comparative analysis of lean vs obese tissue 
by Western. We have also documented these results on Page 15, Line 360.  
We have also analysed serum protein levels. We agree that the protein levels could be affected by other 
processes and discussed this in conjunction with protein levels. 
 
 
Other comments: 
The reviewer requests data on 
4. The insulin sensitivity/resistance of the cohort of subjects for the AT depot study:  
 
Unfortunately we do not have blood samples from time of elective surgery for analysis of fasting glucose or 
insulin from subjects involved in the adipose tissue depot study who underwent elective surgery.  We 
appreciate that data on insulin resistance and sensitivity would be beneficial, however in the depot study 
Point-by Point Rebuttal
analysis we are performing a within-person analysis (subcutaneous versus omental).  Factoring in these 
variables is therefore unlikely to make a difference to the gene expression levels. 
 
 
5. The reviewer believes that the range of HbA1C levels of subjects with T2DM is too wide (from 34 to 62)   
 
The HbA1c of subjects with T2DM depends on the effectiveness of their treatment on glycaemic control.  In 
a clinical context the variance observed is not considered unusual and demonstrates good diabetes control 
which should not affect results.  SEM has now been provided on Page 6, Line 132. 
 
 
6. The groups of patients for the in vitro explant analysis seem to be quite heterogeneous (at least those 
chosen for leptin treatment). It would be important to show the basic biochemical data from the 
patients included in the different groups (fasting glucose, insulin, HOMA-IR, HbA1c) 
 
Unfortunately, as answered previously in question 4, bloods were not taken when adipose tissue samples 
were collected from the tissue bank and therefore we are not able to provide any further information on 
the biochemical data requested.  However, we are performing a within-subject comparison and therefore 
the characteristics at the time of isolation are believed to have less effect on the outcome.  We also 
performed the experiments on 9-10 subjects for each metabolic regulator to try to eliminate bias from any 
outliers.  BMI mean±SEM for the insulin explants has now been provided on Page 8, Line 172. 
 
 
7. The summary provided in Table 2 could include the mean HbA1c levels of subjects in the very low 
calorie diet (VLCD).  
 
Data regarding HbA1c has now been added to Table 2 as requested. 
 
8. The reviewers is concerned about speculative comments: ‘Given that the increase in serum COL6A3 
post-surgery did not reach statistical significance,  the discussion on the relationship between this 
observation and the increased expression of this protein in AT and the reduced fat mass to secrete 
COL6A3 seems too speculative. ‘    
 
We accept the comments made by the reviewer regarding the speculative nature of COL6A3 serum levels 
and have taken these sentences out of the discussion accordingly. It was replaced on Page 17, Line 401 
with the following.  “We observed an increase in COL6A3 in the serum of subjects post-surgery, however 
this did not reach statistical significance, nor did serum levels correlate with COL6A3 expression in SCAT 
(data not shown). Whilst this may require a larger sample size, collagen is also under continuous turnover 
by metalloproteinases and its inhibitors and other sources of COL6A3 levels other than AT. Due to scarcity 
of sample we were unable to directly assess COL6A3 protein levels in AT of these weight loss subjects.   
 
This will form an essential part of future analyses as it will be pertinent to assess whether an increase in 
mRNA expression following weight loss correlates with increased protein production, or whether there are 
post-transcriptional modifications such as reduced translational efficiency or increased protein turnover 
which may modulate COL6A3 protein levels. 
 
9. The reviewer is concerned that the relationship between increased leptin levels and decreased COL6A3 
expression in adipose tissue might not be directly related if, as demonstrated in both rodents and 
human, increased fat mass is accompanied by decreased expression levels of the leptin receptors (Wang 
et al., 2005; Seron et al., 2006). The authors should consider this possibility, also with regards to the 
cartoon shown in Fig. 5.  
 
We appreciate the reviewer’s comments suggesting that although we have demonstrated leptin to have a 
role in regulation of COL6A3 in vitro, this may not translate in-vivo where obesogenic conditions may have 
rendered adipose tissue leptin resistant.  This is a very pertinent point which may indeed affect leptin 
action; however we feel that our choice of subjects for the leptin explant study circumvents this issue.  
SCAT biopsies were taken from four lean (<25kg/m
2
) subjects and five obese (>30kg/m
2
) subjects.  If it were 
the case that obese subjects were very resistant to the effects of leptin then we would have expected to see 
very little change in COL6A3 in these five obese subjects.  As this cohort of obese subjects comprises over 
50% of our explant population we would be left with very little power to observe the effects of leptin on 
COL6A3 expression.  However, when analysing the group of a whole we see striking results on COL6A3 
expression across all subjects tested irrespective of obesity, suggesting that the leptin receptor remains 
sufficiently functional and active within the SCAT of obese subjects.  Although we do appreciate that these 
experiments are taking place outside of the normal environment, we feel that our use of explants 
(containing multiple AT cell types) from multiple BMI donors makes this more physiologically relevant than 
simply using a cell line system.  We have altered Figure 5 to include data relating to insulin resistance and 
mention in the discussion that: ‘Adding to the complexity is the potential of peripheral leptin resistance in 
obesity which may selectively attenuate certain properties but not others’. 
 
Minor questions: 
How were the SCAT biopsies taken in the bariatric weight loss study at the last (second) time point 
tested?  
 
SCAT biopsies were performed under local anaesthesia, small incisions (about 1 inch) were made in the 
abdominal region lateral and close to the umbilicus using a scalpel.  This helped to ensure that we were 
extracting tissue in the same manner as within the original surgical procedure as we aware of the 
differences in gene expression seen when comparing needle and surgical biopsies.  We have included 
words to this effect on Page6, Line 136. 
 
Page 9, line 169: replace "stained with COL6A3" by "immunostained for COL6A3" 
 
As requested – Now on Page 8, Line 181 
 
Page 11, line 258: replace "Figure 1B" by "Figure 1D" 
 
As requested – Now on Page 12, Line 282 
 
Page 15, line 324, and Fig. 4: confirm whether it is COL1A3 or COL1A1 
 
As requested, changed Page 15, Line 360 to confirm that we studied COL1A1 and not COL1A3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reviewer #2 
 
We thank the reviewer their constructive comments and we have addressed their concerns as listed below.  
 
Major points 
1. What is the significance of COL6A3 higher expression in SC vs. OM? The two depots have different 
physiological role and this should be discussed, also with regard to possible implication in insulin 
resistance and type 2 diabetes.  
 
We have now included a paragraph in our discussion commenting on the differential expression results.  
Page 16, Line 384: “Whilst increased SCAT fat mass is metabolically more favourable, fibrosis in SCAT, as is 
also observed in subjects with lipodystrophy, is linked with insulin resistance/diabetes. With the finding of 
a higher expression in SCAT our results question whether COL6A3 takes part in obesity induced fibrosis 
given its reduced expression in obese SCAT”. 
 
2. Although the Authors show increased expression of COL6A3 under diet-induced weight loss, the data 
showing the same result in surgery-induced weight loss has already been reported, as also pointed out 
by the Authors (Henegar  et al., Genome Biol 2008; Dankel et al., Plos One 2010). Therefore, the effect 
of diet is somehow expected and this findings appears not to be so novel.  
 
Other studies of surgery induced weight loss have been performed on a genome-wide level, simply 
reporting up or down-regulation of genes.  Although our study confirms the observation that COL6A3 is 
upregulated following surgery-induced weight loss, we are the first to correlate changes in COL6A3 gene 
expression following surgery induced weight loss with parameters such as circulating leptin which we feel 
makes our data novel. In addition, when comparing dietary with surgical induced weight loss, different 
processes play a role with surgery in which weight loss is typically greater there is also a change in appetite 
hormones and malabsorption which may affect adipose tissue differentially. 
 
3. What kind of cells were used to assess the effects of leptin? This is not clearly explained. Was it the 
stromal fraction? The Authors do not use a differentiation protocol, therefore these are not 
differentiated adipocytes. This should be performed in mature adipocytes, in order to clearly 
demonstrate the effects of leptin. Adipocytes from human tissue cannot simply be plated and cultured, 
they need to attach (as stromal fraction) and then differentiation protocols should be applied to induce 
maturation into adipocytes. 
 
We accept the reviewer’s comments that it was not clear which cells were used to assess the effects of 
leptin.  We have now specifically altered wording in the methods to demonstrate that primary explant 
culture was used to determine the effects of physiological regulators of metabolism (Page 8, Line 186).  In 
addition, we have also included an additional phrase in the results to clearly state that explants are 
fragments of whole adipose tissue (Page 15, Line 340). 
 
As mentioned in our results we had previously determined that COL6A3 is expressed in both the mature 
adipocytes and SVF of adipose tissue.  Therefore the advantage of studying explants as whole tissue in 
which adipocytes are embedded in a collagenous extracellular network containing other cells in the 
entirety of adipose tissue, and not ignoring the SVF contribution, which would have been the case had we 
chosen to study differentiated adipocytes.   
 
4. Figure 3: the error bar for leptin at 100 nM is quite high and is seems strange that the significance is **. 
In addition, the significance values are not reported in the Figure legend for Figure 3. 
 
Please note that this Figure has now been altered to Figure 3A.  As requested we have checked the error 
bar for leptin at 100nM and now report the significance values in the legend for Figure 3.  Significance 
values were determined using a Friedmans One-way ANOVA with a post-hoc Dunns test, calculations have 
been re-checked and the data remains significant (p<0.01) for 100nM leptin. 
 
 
5. Experiments showing signaling pathways on the effects of leptin and COL6A3 could have been 
performed.the Authors state in the Discussion section that this is beyond the scope of their work. 
However, it is a fundamental point to be addressed, otherwise the paper is mostly descriptive.  
If not in primary adipocytes, which however may be obtained from the stromal fraction, signaling 
studies  should be carried out, at least in adipocyte cell lines, such as mouse 3T3-L1 cells.   
 
In light of the reviewers comments we aimed to study the expression of leptin treatment on COL6A3 in 
mouse 3T3-L1 cells, more specifically to utilise blockers of the key leptin signalling pathways to determine 
via which cellular pathway leptin is able to mediate COL6A3 expression.  However, in our differentiated 
mouse 3T3-L1 cells we were unable to identify any change in COL6A3 following leptin treatment (figure 
below from three independent experiments). These results are not necessarily surprising, as (a) the cells 
are mouse derived, and (b) they are a fully committed adipocyte cell line lacking any other cell type 
typically present within physiological adipose tissue and their interaction. Our data therefore support the 
notion that the effects of leptin on COL6A3 expression are likely to be mediated on other cell types present 
in adipose tissue.  To strengthen this argument, and our manuscript, we have included additional data in 
our revised submission (Figure 2C&D) illustrating that the change in adipose tissue COL6A3 following 
bariatric surgery is due to alterations in SVF expression and not adipocytes.  Therefore, it is not surprising 
that we are unable to see changes in a cell line system. Whilst the reviewer feels that the paper is mostly 
descriptive, we would like to highlight the human dietary interventions in this study as well as the study of 
leptin’s effect on collagens in vitro which are functional experiments. 
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Reviewer #3 
 
Major Points 
 
We thank the reviewer for the encouraging comments and have addressed concerns as listed below.  
1. Regarding data on Table 2, statistical significance when comparing baseline week 0 with week 16 in the 
VLCD study should be indicated.  
 
Statistical significance has now been indicated for all variables at week 16 as requested 
 
 
2. The reviewer is asking why BMI correlation was not examined in diet-induced weight change 
studies (VLCD and FF). A correlation analysis of COL6A3 with respect to serum adiponectin 
levels and to HOMA-IR should be performed in the VLCD study.   
 
We chose to study the correlation between COL6A3 and BMI/serum leptin in the LBS study cohort.  This 
population had a relatively wide spread of BMI (44.4±7.3 kg/m
2
) in comparison to the FF group for 
example where the BMI was 21.4±2.4kg/m
2
, or the VLCD group. Therefore we felt that studying the LBS 
cohort would provide greater power to observe significant correlations between the variables tested. 
 
We have now included further analysis within the VLCD cohort.  COL6A3 mRNA expression levels have been 
tested for association with a number of other predictor variables including leptin, adiponectin and HOMA-
IR as requested.  Data are now included in results section, Page 14, Line 313 and in a new table (table 3). 
 
 
3. Data on the effects of leptin treatment of SCAT explants are very interesting and suggest a paracrine 
regulatory mechanism. The reviewer highlights that although not essential, assessment of whether 
leptin receptors are expressed in SCAT explants would be of interest.     
 
Although of potential interest, there is already a substantial body of work in the literature which highlights 
the presence of the leptin receptor in human subcutaneous adipose tissue.  Work performed in 2000 
elegantly showed that leptin receptor mRNA is expressed in human white adipose tissue, and through 
immunohistochemistry demonstrated the presence of the receptor not only on mature adipocytes but also 
on cells of the stromalvascular fraction (Bornstein SR, Diabetes, 2000).  In light of this previous data we 
have chosen not to assess receptor expression within our explants. 
 
4. It would be very interesting to analyze the effects of leptin on the expression of other collagen subunits 
to see whether leptin inhibitory effect is specific or not of COL6A3 expression, and/or whether 
expression of other collagen subunits is oppositely regulated, such as it has been reported by the 
authors to occur with the profibrotic protein SPARC (ref.8 in the manuscript).   
 
We have performed expression analysis for COL1A1, COL3A1, COL4A1 and COL5A3 and included the data 
as supplementary information (Figure 3 B-E). 
 
 
5. Besides reported data on COL6A3 mRNA expression in AT, COL6A3 immunohistological staining 
reported as data not shown should be included in the manuscript.  
 
We have included an additional figure (Figure 4B-D) to show the immunostaining for COL6A3 in omental 
adipose tissue.  We have also documented these results on Page 15, Line 360. 
 
 
 
 
 
6. Data reported in Spencer et al, Am J Physiol Endocrinol Metab 299: E1016-E1027 (2010) should be 
recognized and discussed.    
 
Spencer has studied COL6A1 not COL6A3 expression and we have commented on the respective expression 
of COL6A1 in macrophages as identified by Spencer. 
 
7. In order to state that "diet and surgery-induced weight loss increased COL6A3 in serum" (line 52 
abstract), data depicted on Fig. 2.C. should be statistically significant, and this is not the case. In order to 
reinforce this parameter, could it be possible to measure COL6A3 in serum in the diet-induced weight 
change studies (VLCD and FF)? 
 
Unfortunately there is insufficient sample remaining from the VLCD and FF studies to determine serum 
COL6A3 levels.  We have amended the abstract, Page 3, Line 52 accordingly to take out any information 
relating to COL6A3 serum levels. 
 
 
Minor points 
Please indicate Sweden as the country of the Gothenburg and Linkoping Universities. 
 
Updated on the title page as requested. 
 
COL6A3 antibody used for immunostaining should be indicated. 
 
Included product information on Page 8, Line 185. 
 
 
 Table 2. Please indicate whether data are expressed as mean +/- SD or SEM. 
 
Updated in the footnote of the Table 2. 
 
References. Please provide full reference of article number 6. 
 
Updated in full Page 4, Line 87. 
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Abstract 43 
Fibrosis of adipose tissue (AT) increases AT rigidity, reduces its expandability and contributes to metabolic 44 
dysfunction. Collagen type VI, alpha3 (COL6A3) encodes one subunit of a fibrotic extracellular matrix 45 
(ECM) protein highly expressed in rodent AT. Knock-out of collagen VI in rodent AT led to a significant 46 
improvement in metabolic health in obese, diabetic (ob/ob) mice however, it is unknown whether this 47 
collagen has the same metabolic significance in human AT.  We therefore aimed to undertake a 48 
comprehensive assessment of COL6A3 in relation to human AT and obesity.  Characterisation of COL6A3 in 49 
human AT showed 5 fold higher expression in the stromalvascular fraction compared with adipocyte 50 
expression and significantly higher expression in subcutaneous than omental AT.  In both depots COL6A3 51 
expression appeared to be lowered in obesity, whilst diet and surgery-induced weight loss increased COL6A3 52 
expression in subcutaneous AT. Leptin treatment caused a dose dependent decrease in COL6A3 expression 53 
although no effect was seen with insulin or glucose treatment and no difference observed in subjects with 54 
diabetes.  In addition, we found that the collagen expression profile in humans differs significantly from 55 
rodents as COL6A3 does not appear to be the predominant collagen in adipose, muscle or liver. Our findings 56 
oppose those initially seen in rodent studies and most importantly, demonstrate a direct regulation of 57 
COL6A3 by leptin.  This highlights the importance of a paracrine leptin signalling pathway in human AT and 58 
suggests an additional mechanism by which leptin can regulate ECM composition and with it AT 59 
expandability. 60 
 61 
 62 
 63 
 64 
 65 
 66 
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Introduction 67 
Within adipose tissue (AT), mature adipocytes are responsible for the safe storage of dietary triglycerides 68 
during times of positive energy balance.  Structural support for these lipid-laden cells is provided by the 69 
adipose tissue extracellular matrix (ECM), a dense network of fibrous proteins embedded in a proteoglycan-70 
rich, gel like substance (1).  The ECM provides structural integrity and transduces sheer stress away from the 71 
cells (2).  Relative composition of the ECM and ratios of collagen subunits contribute to the mechanical 72 
properties of the tissue, such as tensile and compressive strength and elasticity (1).  To maintain metabolic 73 
health, it is essential for the collagen network to retain flexibility (3).  Dynamic remodelling of the ECM is 74 
key to allow tissue growth at times of positive energy balance by uncompromised cellular expansion, a 75 
process which occurs by adipocyte hypertrophy and adipogenesis (4). 76 
Recently, studies relating to the composition of adipose ECM in obesity have generated substantial interest.  77 
Henegar et al demonstrated deregulated ECM composition in the AT of obese human subjects (5).  Analysis 78 
of the AT transcriptomic signature demonstrated differential expression of multiple ECM genes between lean 79 
and obese subjects whilst histological analysis revealed increased interstitial fibrosis in obesity (5).  Fibrosis 80 
is defined as an increased accumulation of insoluble fibers, described by increased synthesis, accumulation 81 
and reduced degradation of collagens (3).  Increased AT fibrosis results in increased ECM rigidity and 82 
reduced expandability, and it is hypothesized that this drives ectopic lipid deposition, contributing to insulin 83 
resistance and impaired metabolic health.  In our previous work we have shown that human omental (OM) 84 
tissue, which has a higher fiber content than abdominal subcutaneous (SC) tissue, is restricted with 85 
biomechanical tensile testing resulting in a higher elastic modulus, confirming that increased stiffness and 86 
decreased expandability are linked with increased collagen deposition in this depot (6). 87 
In support of this initial work, microarray analysis of human AT following overfeeding and weight gain has 88 
demonstrated increased expression of multiple ECM genes (7), whilst more specifically levels of the ECM 89 
regulator and profibrotic protein SPARC have been shown to be upregulated in obese AT and associated 90 
with insulin resistance in humans (8).  In rodent studies, Chun et al observed that ablation of an ECM 91 
remodelling enzyme, matrix metalloproteinase 14 (MMP14), prevented development of white AT leading to 92 
5 
 
a lipodystrophic phenotype in null mice (9) whilst the study of an obese, diabetic rodent model highlighted 93 
the ubiquitous up-regulation of multiple collagen subunits compared to control animals (2).  Interestingly, 94 
amelioration of one collagen subtype, COL6, in obese rodents (ob/ob) led to increased AT expansion, 95 
improved insulin sensitivity and a reduced inflammatory profile, suggesting that targeting of this collagen 96 
subunit may be beneficial for the appropriate storage of triglycerides in AT (2).  However, to date very little 97 
work has characterised the role of COL6A3 in human obesity and it is unclear to what degree COL6A3 98 
contributes to the total ECM collagen fraction in human AT.  As ECM remodelling genes are upregulated 99 
with overfeeding (7) we hypothesise that COL6A3 will be increased with weight gain and obesity and 100 
downregulated with weight loss.  Given the observation that COL6A3 expression is higher in an insulin 101 
resistant population of Asian origin (2) we postulate that COL6A3 expression will be higher in the AT of 102 
subjects with Type 2 diabetes and will be regulated by treatment with glucose or insulin. 103 
The aims of our study were therefore to perform a comprehensive assessment of COL6A3 in human AT; to 104 
study its role in human obesity and diabetes, to assess the effect of weight change on expression levels and 105 
finally to identify potential regulatory mechanisms which drive COL6A3 expression. 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
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Materials & Methods 116 
Subjects for AT depot study 117 
Abdominal SC and OMAT biopsies were obtained from subjects undergoing elective gynaecological surgery 118 
at the Royal Devon and Exeter Hospital, Exeter, as part of an ongoing tissue bank initiative.  All samples 119 
were collected from female subjects with full ethical consent.  Subjects with diabetes or malignant diseases 120 
were excluded.  Lean and obese subjects were matched on a pair-wise basis for age, gender, smoking status 121 
and activity levels where known and had the following characteristics: Lean vs Obese (n=15 pairs): Age 122 
(years) 44.1±11.6 vs 44.7±11.5 (mean ± SD), p=ns; BMI (kg/m
2
) 22.5±1.6 vs 33.7±5.5, p<0.001.   123 
Individuals were selected from this cohort for within-subject depot specific analysis if both SC and OMAT 124 
was available (n=19, Age 45.8±13.6 years, BMI 28.4±7.7 kg/m
2
). 125 
Subjects for diabetes comparison study 126 
All subjects used for the diabetes comparison analysis were female.  SCAT biopsies were taken from Type 2 127 
diabetes (T2DM) subjects undergoing bariatric surgery or from those enrolled onto a clinical trial 128 
intervention study at the Exeter Medical School.  Samples from subjects without diabetes were collected via 129 
routine surgery as detailed above.  All samples were collected with full ethical consent.  Briefly diabetic and 130 
non-diabetic subjects were matched on a pair-wise basis for gender and BMI (36.1 kg/m
2
 ± 7.6 vs 36.8 ± 6.4, 131 
p=ns, n=9 pairs).  HbA1c (mean±SEM) of subjects with T2DM was 50.7±3.0 mmol/mol (range: 34-62). 132 
Subjects for bariatric weight loss study 133 
UK subjects undergoing weight-loss surgery (n=11) had SCAT biopsies taken during laparoscopic bariatric 134 
surgery and on average 9.5±1 months subsequently.  Biopsies during the second visit were taken under local 135 
anaesthesia.  A small incision was made in the abdominal adipose tissue lateral and close to the umbilicus 136 
using a scalpel to permit SCAT sampling.  Subjects were included in the study if they were aged between 18-137 
60 years and had no history of inflammatory disease, malignancy, uncontrolled thyroid disease, muscle 138 
conditions or chronic liver injury and had not recently been treated with steroids or hormone replacement 139 
therapy.  All subjects had fasting bloods taken during both visits as well as a multitude of anthropometric 140 
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measurements including weight, waist circumference and body composition (measured by Air Displacement 141 
Plethysmography technology, Bodpod, Cranlea, UK).  This study was approved by the National North West 142 
3 Research Ethics committee-Liverpool East.  Patient characteristics are reported in Table 1. Independently,  143 
severely obese subjects undergoing sleeve gastrectomy as previously described (10) were recruited and 144 
consented in Norway with approval by the Regional Committee for Medical Research Ethics (REK) in 145 
Western Norway.  146 
Very low calorie diet study 147 
To assess the effect of dietary induced weight loss, 24 obese subjects (BMI 37.6±4.9kg/m
2
) undertook a 148 
450kcal/day very low calorie diet (VLCD) for 16 weeks with a subsequent 2 week re-feeding period.  Study 149 
assessments were performed at the beginning of the study (week 0), at two intervals throughout the study 150 
(week 8 and 16) and two weeks after the VLCD study (week 18) with SCAT biopsies obtained at each time 151 
point.  The study was conducted in Gothenburg and approved by The Regional Ethics Review Board.  152 
Patient characteristics have been reported previously (8,11-13) and a summary is provided in Table 2.  153 
Analyses of association between clinical variables and COL6A3 expression were performed using 154 
Generalized Estimating Equations in which COL6A3 mRNA expression was set as the dependent variable, 155 
and values of each clinical variable, age, gender and week of follow-up were set as independent variables.  156 
Correction was done for repeated measurements in the same individual. All variables have been log 157 
transformed to perform the tests of association. 158 
Hyperalimentation study 159 
To study the effect of overfeeding, 6 lean subjects (BMI 21.4±2.5kg/m
2
) were enrolled onto a fast food diet 160 
for 4 weeks in which caloric intake was doubled and exercise restricted to 5000 steps/day. The study 161 
protocol has previously been reported in detail (14) and was approved by The Regional Ethics Committee in 162 
Linköping.  A summary of subject characteristics is provided in Table 2.  Subjects had SCAT biopsies taken 163 
at the start (week 0) and end (week 4) of the study.  Computed tomography (CT)-scans were also performed 164 
to assess the size of SCAT, visceral AT (VAT) and total AT ( TAT) using a CT HiSpeed Advantage, RP 2.5 165 
(GE Medical Systems, Milwaukee, Wisconsin) as previously described (15). 166 
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Subjects for in vitro explant analysis 167 
Matched OM and SCAT biopsies were obtained from 28 female subjects undergoing elective gynaecological 168 
surgery as detailed above.  The cohort of 28 was split into three groups and 9 matched biopsies processed 169 
and treated with recombinant human (rh) leptin, 10 with glucose and 9 with rh insulin.  Briefly the 170 
characteristics of the individual treatment groups were: Leptin (mean±SD): Age 44.8±9.0 years, BMI 171 
30.2±8.3kg/m
2
; Insulin: Age 41.3±9.5years, BMI 25.5±5.5kg/m
2
; Glucose: Age 45.1±13.3 years, BMI 172 
27.1±3.3 kg/m
2
. 173 
Adipose tissue processing 174 
AT biopsies for depot-specific analysis or for assessment of weight change related expression were snap 175 
frozen in liquid nitrogen at the time of biopsy before being transferred to -80°C for long-term storage. AT 176 
samples for in vitro explant analysis were placed into sterile containers containing collection media (1x 177 
Hank’s balanced salt solution (HBSS), 0.01M Hepes, 2.5µg/ml Amphotericin B and 0.05mg/ml Gentamicin) 178 
for transport to the laboratory.  179 
Immunohistochemistry 180 
Immunohistochemistry was performed as previously described (16). In brief, formalin-fixed, paraffin-181 
embedded AT sections were cut at a thickness of 4µm and collected on positive charged microscope slides. 182 
De-paraffinisation, rehydration and immunohistochemistry were carried out by the Bond™-MAX autostainer 183 
at room temperature. Slides were treated with or without COL6A3 antibody (1:100; Ab49273 [Abcam]).  184 
Staining was also performed in testes as a positive control. 185 
Primary explant culture to assess physiological regulators of metabolism 186 
Samples were processed for explant culture using a modification of Fried and Moustaid-Moussa (17).  187 
Briefly, samples were washed in 1xPBS (1% pen/strep) and minced into 5-10mg pieces. Tissue was rinsed 188 
through a 230µm nylon mesh using 1xPBS and M199 culture media.  Samples were transferred to six well 189 
plates (~250mg/well) with 3ml M199 media, supplemented with 5% foetal calf serum and 1% 190 
penicillin/streptomycin.  Explants were cultured for 24 hours at 37°C under an atmosphere of 5% carbon 191 
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dioxide/95% air in the presence of varying concentrations of glucose, rh leptin (Cambridge Biosciences, 192 
UK), or insulin (Sigma Aldrich, UK).  All treatment conditions were performed in triplicate. 193 
Adipocyte isolation protocol 194 
AT biopsies were minced into small fragments using scalpels before sequentially washing four times in 1x 195 
Hank’s buffered salt solution (HBSS) to remove contaminating blood.  Tissue was enzymatically digested in 196 
1mg/ml collagenase (Gibco, Life Technologies) in HBSS for 1 hour at 37°C with gentle agitation.  Digested 197 
tissue was centrifuged at 360xg for 5 minutes (4°C) to separate out the lipid filled floating adipocytes from 198 
the stromalvascular fraction (SVF).  Both fractions were washed in HBSS to remove residual collagenase 199 
solution before RNA extraction.   200 
RNA extraction and processing 201 
Total RNA from AT acquired in the VLCD study was extracted using the Qiagen RNeasy lipid tissue kit as 202 
per manufacturer’s instructions. RNA from all other samples was extracted using the phenol-chloroform-203 
guanidinium-thiocyanate method (18).  Briefly ~100mg tissue was homogenised in Tri reagent (Life 204 
Technologies) using a Retsch Mixer Mill MM400 in accordance with manufacturer’s instructions.  RNA 205 
quantity was determined spectrophotometrically using Nanodrop technology.  RNA was treated with DNase 206 
I (ThermoScientific) to remove residual genomic contamination before 500ng was reverse transcribed in a 207 
random primed single strand synthesis reaction using high capacity reverse transcriptase (Life Technologies). 208 
Gene expression analysis 209 
COL6A3 expression in subjects in the VLCD study was determined using the Human Genome U133A DNA 210 
microarray (Affymetrix) whilst in the hyperalimentation study, expression was determined using HG-211 
U133Plus2.0 (Affymetrix) as previously described (19).  COL6A3 expression in all other samples was 212 
determined using qRT-PCR with Taqman technology.  Briefly, cDNA was diluted in 0.01M Tris HCl before 213 
amplification with a COL6A3 specific expression assay (Hs00915125_m1) or expression assays for the 214 
housekeeping genes PPIA (Hs99999904_m1) or UBC (Hs00824723_m1) using Universal PCR mastermix 215 
(Life Technologies).  All samples were amplified in triplicate for each assay and were run alongside a 216 
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standard curve to allow assay efficiency determination.  Expression analysis of COL1A1 (Hs00164004_m1), 217 
COL3A1 (Hs00943809_m1), COL4A1 (Hs00266237_m1) and COL5A3 (Hs00210526_m1) were also 218 
determined in AT explants following leptin treatment.  COL6A3 expression change following bariatric 219 
surgery was determined, alongside other collagen subunits, using a Taqman Low-Density Array, following 220 
normalising to the geometric mean of 4 housekeeping genes (PPIA, UBC, GAPDH and PGK1).  221 
Amplification was performed using an ABI7900 thermal cycler with the following cycling parameters: 50°C-222 
2 minutes, 95°C-10 minutes, 40 cycles (95°C-15 seconds, 60°C- 1 minute).  mRNA expression analysis in 223 
the Norwegian bariatric subjects was normalised to TBP.  Gene expression levels were calculated using the 224 
2^
-ΔΔCt 
analysis method modified by Pfaffl (20) and are presented as Arbitrary Units (AU). 225 
Serum analysis 226 
Blood was taken from subjects during and 9 months post bariatric surgery for analysis of adipokines, glucose 227 
and insulin.  The Homeostatic Model Assessment (HOMA) method was used to assess beta-cell function 228 
(HOMA-β) and insulin sensitivity (HOMA-IR) (21).  Serum insulin levels were assessed using Immunoassay 229 
from Cobas-Roche (Sussex, UK) with sensitivity of 0.2µU/ml and intra-assay coefficients of variation of 230 
2.5-4.9%.  Serum leptin levels were assessed using ELISA from Millipore (Watford, UK) with sensitivity of 231 
0.5ng/ml with intra-assay coefficients of variation of 2.6-4.6%.  COL6A3 ELISA was purchased from USCN 232 
Life Science (E92148HU, Oxford Biosystems, UK) with sensitivity of 13.4pg/ml and intra-assay coefficient 233 
of variation of <10%.  All ELISAs were performed in line with manufacturers’ guidelines.   234 
Statistical analysis 235 
All data are presented as mean±SEM unless otherwise stated.  Within-subject, lean versus obese and diabetic 236 
versus non-diabetic comparisons were made using the non-parametric Wilcoxon signed rank test.  237 
Comparison before and after weight change within subjects in the VLCD and hyperalimentation study were 238 
performed with a paired two-tailed t-test.  For BMI and COL6A3 expression analysis, data were log 239 
transformed to achieve normality before Pearson Correlation Coefficients were determined.  For explant 240 
studies with varying treatment conditions, comparisons were made using Friedman’s ANOVA with post-hoc 241 
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Dunn’s test.  Statistical analysis was performed using IBM SPSS v18 (SPSS, Chicago, US) and statistical 242 
significance achieved if p<0.05. 243 
 244 
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Results 262 
COL6A3 depot specific expression 263 
To begin, we determined in which AT cell type and depot COL6A3 predominates.  AT is comprised not only 264 
of adipocytes but also fibroblast derived preadipocytes, endothelial cells and immune cells which 265 
collectively comprise the stromalvascular fraction (SVF).  To determine which cell types contribute to AT 266 
COL6A3 expression, omental AT from six healthy subjects was fractionated using collagenase to separate 267 
mature adipocytes from the SVF.  Expression analysis within these distinct cellular populations 268 
demonstrated that AT COL6A3 mRNA levels are predominantly contributed to by cells of the SVF.  Mean 269 
expression level (±SEM) within this fraction was 2.0±0.4 AU compared to 0.4±0.1 AU in mature adipocytes 270 
(p<0.05, Figure 1A). 271 
Next we analysed the within-subject depot specific expression of COL6A3 in two independent cohorts, on 272 
both occasions observing significantly higher COL6A3 expression within abdominal SC compared to OMAT 273 
(Figure 1B&C).  In the first population, a cross-sectional cohort of healthy female subjects, we observed that 274 
COL6A3expression was 1.2±0.1 AU (mean±SEM) in SC tissue compared to 0.9±0.1 AU within OM samples 275 
(n=19, p<0.01, Figure 1B).  In a separate cohort of subjects undergoing bariatric surgery, consisting of both 276 
men and women, we again observed the same depot specific trend with SCAT showing higher expression 277 
than OMAT (SC v OM: 2.0±02 vs 1.2±0.1AU, n=11, p<0.01, Figure 1C). 278 
COL6A3 expression and BMI 279 
To determine whether COL6A3 is differentially expressed with obesity, our Exeter depot cohort was 280 
subdivided into lean (BMI<25kg/m
2
: 22.5±1.6 [mean±SEM] kg/m
2
) and obese (≥25kg/m2, 33.7.4±5.5kg/m2) 281 
subjects.  When comparing expression levels within OMAT we saw a trend towards reduced expression 282 
within obese subjects compared to lean (0.7±0.1 vs 1.0±0.1 AU, n=13, p=0.22, Figure 1D) although this did 283 
not reach statistical significance.  A similar trend was also observed in SCAT although this once again failed 284 
to reach statistical significance (obese vs lean: 1.1±0.1 vs 1.3±0.1 AU, n=11, p=0.47, Figure 1D). SCAT is 285 
essential for buffering surplus free fatty acids in times of energy excess.  Dysregulation of ECM within this 286 
depot is hypothesised to increase fibrosis, reducing the ability of AT to expand by suppressing adipogenesis 287 
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and limiting adipocyte hypertrophy, all of which contribute to ectopic fat deposition.  Diversion of 288 
triglyceride storage from subcutaneous to ectopic tissues, as seen in lipodystrophy, increases insulin 289 
resistance and the risk of diabetes (22). With this in mind we focussed the majority of our further analysis on 290 
assessing the expression of COL6A3 in the SCAT depot. 291 
COL6A3 expression and diabetes 292 
Kahn et al demonstrated significantly higher levels of COL6A3 in a population of Asian Indians who show 293 
increased susceptibility to insulin resistance (2).  To ascertain whether this correlation with impaired insulin 294 
sensitivity is true in other ethnic populations we determined COL6A3 expression in the SCAT of Caucasian 295 
subjects with or without T2DM.  All subjects were individually matched for gender and BMI.  No significant 296 
difference in expression was determined between these two groups (0.8±0.1 vs 0.9±0.2 AU, n=9, p=ns, data 297 
not shown).  298 
COL6A3 expression and weight change 299 
Three independent cohorts were used to assess the effects of weight gain or weight loss on SCAT COL6A3 300 
expression levels. (1) Subjects gaining weight after four weeks of fast food dieting in the hyperalimentation 301 
study as described above, (2) subjects undergoing a 16 week VLCD diet followed by 2 weeks of refeeding, 302 
and (3) subjects before and after bariatric surgery.  COL6A3 expression was determined in SCAT biopsies 303 
before and after each of these dietary or surgical interventions. 304 
(1) COL6A3 and hyperalimentation  305 
SCAT biopsies were taken from lean subjects at baseline and following four weeks of a high calorie diet 306 
(Table 2).  As shown in Figure 2A, COL6A3 expression was not significantly altered despite significant 307 
weight gain at the cessation of the study (week 0 vs week 4 [mean±SEM]: 2036±803 vs 2574±641 AU, n=6, 308 
p=ns). 309 
(2) COL6A3 and VLCD 310 
As described in the method section, biopsies were taken from 24 subjects at baseline and following 16 weeks 311 
of a low calorie diet (Table 2). As shown in Figure 2A, COL6A3 expression increased significantly with 312 
dietary induced weight loss (week 0 vs week 16 [mean±SEM]: 1725±76 vs 2142±98AU, n=24, p< 0.001).  313 
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Refeeding without weight gain (weeks 16-18) did not significantly affect COL6A3expression levels.  We 314 
next determined the association between COL6A3 and metabolic parameters during the course of the weight 315 
loss intervention (Table 3).  COL6A3 mRNA levels negatively correlated with BMI, HbA1c and HOMA-IR 316 
(if uncorrected for BMI). Of interest, COL6A3 was found to be negatively associated with both leptin mRNA 317 
in SCAT (p<0.0001) and serum leptin levels (p=0.0015). 318 
(3) COL6A3 and bariatric surgery induced weight loss 319 
SCAT biopsies were taken from 11 obese subjects during bariatric surgery and on average 9.5±1.1 months 320 
post-surgery.  In this time period subjects lost on average 26.1kg, reducing their BMI by 8.5kg/m
2
, and 321 
improving a number of other associated metabolic parameters as shown in Table 1.  Following surgery, 322 
SCAT COL6A3 expression was increased 1.6-fold (2.0±0.2 vs 3.2±0.6 AU, n=11, p<0.05, Figure 2B).  There 323 
was a concomitant increase in serum COL6A3 levels post-surgery (133.3±12.2 vs 146.5±11.2ng/ml, n=8, 324 
p=ns, Fig 2E) whilst a significant reduction in circulating leptin levels was also observed at this time point 325 
(57.7±7.2 [mean±SEM] vs 18.2±5.1ng/ml, n=11, p<0.01, Figure 2F).  Bivariate-Pearson correlation analysis 326 
highlighted a significant negative association between SCAT COL6A3 expression and BMI (r=-0.57, p<0.01, 327 
Figure 2G), an association which was also observed when correlating SCAT COL6A3 expression and 328 
circulating serum leptin levels (r=-0.69, p<0.01, Figure 2H). 329 
To determine from which cell type the changes in COL6A3 mRNA were arising, we measured COL6A3 330 
mRNA expression in adipocytes and SVF cells from an independent cohort of severely obese subjects before 331 
and one year after bariatric surgery (n=5, age 44.2±9.5 years, BMI   46.44± 4.8[mean±SEM] before and 332 
33.34±6.3kg/m
2
 after surgery).  In isolated adipocytes there was no consistent change in COL6A3 expression 333 
after profound surgical weight loss (p=0.937) (Figure 2C). On the other hand, in the SVF we found a 334 
significant 3.6-fold increase in COL6A3 mRNA expression (p=0.043) (Wilcoxon signed rank test) (Figure 335 
2D). 336 
COL6A3 expression and physiological regulators of metabolism 337 
The negative correlation between leptin and AT COL6A3 in both the diet and surgery-induced weight loss 338 
cohorts prompted us to investigate whether COL6A3 may be directly modulated by physiological regulators 339 
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of metabolism.  In particular we wanted to study regulation by leptin and, due to the presumed association 340 
with insulin resistance as previously reported (2), we also wanted to assess modulation by glucose and 341 
insulin.  SCAT explants (1mm
3
 whole adipose tissue fragments) were treated with varying concentrations of 342 
rh leptin (0.01nM, 10nM and 100nM), insulin (0.01nM, 10nM and 100nM) and glucose (5mM, 10mM and 343 
20mM) for 24 hours in culture and expression levels compared to control explants (explants cultured for 24 344 
hours in the absence of the metabolic regulator).  Treatment with insulin and glucose had no effect on 345 
COL6A3 mRNA expression (Insulin: Control v 0.01nM vs 10nM vs 100nM – 1.5±0.3 vs 1.7±0.4 vs 1.5±0.3 346 
vs 1.4±0.3 AU, n=9, p=ns.  Glucose: Control vs 5mM vs 10mM vs 20mM – 1.8±0.3 vs 1.7±0.3 vs 1.6±0.2 vs 347 
1.5±0.2 AU, n=10, p=ns).   Treatment with leptin however caused a dose-dependent decrease of COL6A3 348 
(Leptin: Control vs 0.01nM vs 10nM vs 100nM – 1.6±0.2 vs 1.3±0.1 vs 1.1±0.1* vs1.1±0.3** AU, n=9, 349 
*p<0.05, **p<0.01, Figure 3A).  Leptin treatment also caused a significant downregulation of COL1A1 at 350 
100nM vs Control (0.47±0.08 vs 0.68±0.07, n=9, p<0.05, Figure 3B).  There was no change in expression of 351 
any other collagen subunit when cultured with leptin for 24 hours. 352 
AT ECM collagen distribution 353 
In order to establish whether, like rodents, COL6A3 is the predominating collagen in human AT, we 354 
determined the expression profile of multiple collagen subunits across a range of metabolically relevant 355 
tissues.  Using TLDA gene expression technology we simultaneously determined the collagen expression 356 
profile in human AT, liver and muscle biopsies, obtained from subjects undergoing bariatric surgery 357 
(described above).  COL5A3 was most highly expressed within liver, with levels four-fold higher than any 358 
other of the tested collagen subunits (Figure 4A).  Interestingly, although COL6A3 is one of the most 359 
predominantly expressed collagens within muscle, this same expression pattern does not translate to AT, 360 
with COL6A3 expression within both OM and SCAT being strikingly lower than COL1A1, COL3A1 and 361 
COL4A1 (Figure 4A). Immunostaining showed that COL6A3 is distributed in the pericellular space of 362 
omental AT (Figure 4B). 363 
 364 
 365 
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Discussion 366 
The ability of AT to expand in times of positive energy balance and retract during negative energy balance is 367 
an essential homeostatic mechanism, permitting buffering of daily lipid flux and mobilisation of an essential 368 
fuel source respectively.  For AT to expand, remodelling of the ECM must occur, permitting both growth of 369 
existing adipocytes and differentiation of precursor cells.  Increased deposition of fibrous proteins within the 370 
ECM has been shown to lead to increased rigidity and reduced AT expandability (9), and increased SCAT 371 
fibrosis is considered to be a driving force behind ectopic fat deposition.  The negative health implications of 372 
ectopic fat deposition are clearly seen in patients with lipodystrophy, where storage of triglycerides in sites 373 
external to AT correlates with insulin resistance and diabetes (22).  Khan et al. have previously highlighted 374 
the metabolic benefits of knocking out a fibrous ECM collagen subunit (COL6) in a genetically predisposed 375 
obese rodent model (2).  Ob/ob mice, who are otherwise metabolically compromised, were shown to have 376 
increased insulin sensitivity, despite hypertrophic adipocytes, and a reduced AT inflammatory profile when 377 
COL6 was knocked out (2).  Evidence from this study suggested that in rodents at least, accumulation of 378 
COL6 may be a significant factor contributing to reduced AT expandability with overfeeding (2). 379 
Our study investigates whether the same applies to human physiology. Our data suggest that COL6A3 380 
expression is significantly higher in SCAT when directly compared to OMAT using within-subject paired 381 
analysis.  This expression pattern was observed not only in a cross-sectional population of healthy female 382 
subjects, but also in subjects undergoing bariatric surgery, highlighting that the depot specific differences are 383 
not driven by BMI, but remain true across all weight ranges. Whilst increased SCAT fat mass is 384 
metabolically more favourable, fibrosis in SCAT, as is also observed in subjects with lipodystrophy, is 385 
linked with insulin resistance/diabetes (16, 22). With the finding of a higher expression in SCAT our results 386 
question whether COL6A3 takes part in obesity induced fibrosis given its reduced expression in obese SCAT 387 
given our observation of a consistent trend of lower expression with increasing BMI.  Interestingly, our 388 
findings are in contradiction to those reported by Pasarica et al (23).  In their depot specific analysis, 389 
significantly higher COL6A3 expression levels in visceral compared to SCAT were found alongside a 390 
positive correlation between BMI and COL6A3 SCAT expression (23).  There are multiple explanations as to 391 
why our observed expression patterns vary including (1) differences in the site from which biopsies were 392 
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obtained, (2) variations in the methodology used to obtain biopsies, (3) design of probes to accurately 393 
quantify gene expression levels and/or, (4) variations in subject gender with lower COL6A3 expression in 394 
women (23).  To gain conclusive results regarding the expression levels of AT COL6A3 with variable fat 395 
mass, we performed a more comprehensive assessment of COL6A3 expression following diet and surgery-396 
induced weight loss and dietary-induced weight gain, in subjects matched for gender where indicated.  397 
 398 
In line with the findings in our initial cross-sectional study we found that weight loss, both diet and surgery-399 
induced, led to an increase in SCAT COL6A3 mRNA expression.  Our findings are in line with other 400 
analyses in which COL6A3 expression was found to be elevated following bariatric surgery (5,24), however 401 
as far as we are aware, we are the first to show that there is also a significant increase in expression 402 
following diet-induced weight loss, which was of a similar magnitude to surgery-induced weight loss. We 403 
observed an increase in COL6A3 in the serum of subjects post-surgery, however this did not reach statistical 404 
significance, nor did levels correlate with COL6A3 expression in SCAT (data not shown).  Whilst this may 405 
require a larger sample size, it is pertinent to remember that collagen is under continuous turnover by 406 
metalloproteinases and its inhibitors and other sources of COL6A3, other than AT, are likely to dilute any 407 
association. Due to scarcity of sample we were unable to directly assess COL6A3 protein levels in AT of 408 
these weight loss subjects.  We extended our study to also assess COL6A3 expression in relation to the 409 
hyperalimentation-induced weight gain but were unable to identify a significant change in expression. 410 
Though the number of AT biopsies obtained for this study was small (n=6) (as subjects who failed to adhere 411 
to the diet and/or failed to gain weight were excluded), the biopsies assessed were from subjects who 412 
achieved substantial weight gain as shown in Table 2 (14).  Of note, the weight gain observed in our 413 
hyperalimentation study is of a similar magnitude to the weight gain reported in Pasarica’s study, in which a 414 
significant increase in COL6A3 was reported (23).  Lack of correlation in our study may be explained by the 415 
small effect of weight gain on COL6A3, the relatively short duration of the study or higher baseline COL6A3 416 
levels in our subjects, which due to the low BMI of our subjects are less likely to increase, as suggested by 417 
Pasarica (23). Similarly, and consistent with this, we did not find a change in COL6A3 expression after 418 
refeeding following dieting in the VLCD study.  419 
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 420 
We have not found elevated or different levels of COL6A3 in subjects with T2DM when compared to BMI-421 
matched non-diabetic subjects, which is similar to previous findings (23), nor did we observe changes in 422 
COL6A3 expression in response to glucose or insulin treatment.  However, one of the most interesting 423 
observations from our study is the strong correlation between COL6A3 expression and leptin.  Leptin is 424 
secreted from adipocytes in proportion to fat mass and is a regulator of satiety (25).  In patients undergoing 425 
bariatric surgery, and those on a VLCD, we see a significant negative correlation between SCAT COL6A3 426 
expression and circulating serum leptin levels, suggesting that as leptin levels (and therefore obesity) 427 
increase, COL6A3 mRNA levels decrease.  To further investigate this novel association we treated primary 428 
human SCAT explants with rh leptin and observed a dose-dependent reduction in COL6A3 expression with 429 
increasing leptin concentration.  Our data therefore suggest a direct regulatory effect of leptin on the 430 
expression of COL6A3.  Leptin receptors are present on the surface of adipocytes and autocrine/paracrine 431 
leptin signalling within adipocytes is known to occur to induce functions such as lipolysis (26,27).  In 432 
rodents, AT-specific knockout of the leptin receptor was shown to result in increased adiposity and an 433 
impaired metabolic phenotype (28) whilst experimentally induced hyperleptinaemia was shown to deplete fat 434 
mass, which may in part be explained via increased lipolysis (29).  This data clearly points to the presence of 435 
a paracrine feedback mechanism within AT by which leptin is controlling fat mass.  There is also evidence of 436 
a paracrine feedback mechanism in human AT.  In 2012, Singh et al demonstrated that leptin treatment of 437 
differentiating human adipocytes resulted in increased expression of the plasma membrane protein Caveolin 438 
1, which in turn impaired leptin signalling preventing leptin-mediated reduction in lipid accumulation (30).  439 
This may suggest that in humans, feedback mechanisms exist by which leptin is able to mediate the storage 440 
of triglycerides in a safe manner in times of triglyceride excess and hyperleptinaemia.   441 
Leptin binding to its receptor has been shown to activate a number of downstream signalling pathways and 442 
secondary messengers including ERK and JAK/STAT (30), all of which could be hypothesised to modulate 443 
expression levels of COL6A3.  Investigation of the specific mechanisms of regulation were deemed to be 444 
beyond the scope of this manuscript but will warrant further investigation to determine how physiological 445 
regulators of metabolism are able to modulate ECM gene expression levels.  Our observation that COL6A3 446 
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expression levels may change with weight only in the SVF, compared to adipocytes, needs further 447 
investigation.  In particular, understanding the relevance of Col6 in endothelial maturation and its expression 448 
in newly formed vessels will be pertinent given the vascular rarefaction observed with obesity.  This may go 449 
some way to explaining the higher levels observed with lower BMIs (31,32).  Collagen VI is also expressed 450 
in AT macrophages as recently shown by Spencer at al (33)  who identified an association between COL6A1 451 
expression and AT inflammation and reduced insulin sensitivity.  However, we studied more specifically 452 
COL6A3 expression and COL6A3 immunostaining and therefore our results are unlikely to be directly 453 
comparable with this study. Previous studies suggest non-coordinate regulation of the mRNA expression of 454 
COL6 alpha chains such as in wound healing (31) which may explain the different characteristics. 455 
 456 
Our observation that AT COL6A3 expression does not increase with obesity or metabolic parameters in 457 
human subjects is in stark and direct contradiction to previous studies performed in rodents (2).  Although it 458 
is feasible that the disparity in findings may be due to species differences, we feel another possible 459 
explanation may pertain to the system in which COL6 was knocked down in rodents.  Initial studies 460 
performed in db/db mice demonstrated elevated levels of AT Col6a3 compared to wildtype animals whilst 461 
knockout of COL6 was performed in an ob/ob model (2).  It is pertinent to consider that in both of these 462 
models of obesity and diabetes, the leptin signalling pathway has been genetically silenced at the level of the 463 
receptor or the adipokine respectively.  Our data clearly demonstrate the importance of a paracrine leptin 464 
signalling pathway in regulation of human AT COL6A3 expression, and it is therefore possible that loss of 465 
leptin signalling in the rodent models may be driving the increase in Col6a3, a phenomenon which may not 466 
necessarily be seen in physiological obesity, when leptin levels are high.  Therefore in the future, it may be 467 
relevant to assess the effects of COL6 knockdown in an in-vivo situation in which leptin and its receptor 468 
remain functional.   469 
 470 
Leptin is a pro-inflammatory cytokine and we have previously shown it is able to potently increase levels of 471 
the profibrotic matricellular protein SPARC in human AT (8).  This would suggest leptin influences ECM 472 
20 
 
fibrosis.  Data from our current study however suggests that leptin is also able to downregulate ECM 473 
components in an obesogenic environment.  Although rodent data suggest Col6a3 to be the most highly 474 
expressed collagen in AT (2), our human data suggest that the contribution of COL6A3 to total collagen 475 
levels is minimal.  Similarly immunohistochemical data from human subjects has shown that COL6A3 does 476 
not reside within fibrous bundles of AT, but was found by us and by others in the pericellular space 477 
surrounding adipocytes (23,34).  Its position around the adipocytes may if in surplus limit the expandability 478 
of existing fat cells by increasing cell rigidity as demonstrated by Chun by which a rigid network limits 479 
adipocyte hypertrophy and adipogenesis (9).  This would be a concern should we have found COL6A3 to be 480 
increased in obesity yet our findings do not support its contribution to AT fibrosis if we assume to reserve 481 
this term to describe the obesity associated increase in AT collagens. 482 
 483 
Leptin modulates ECM remodelling and as such its expansion by several mechanisms which we have 484 
outlined in a diagrammatic flowchart (Figure 5).  It is expressed and secreted in relation to fat mass and 485 
upregulated by hypoxia, which amongst others develops as result of growing oxygen diffusion distance 486 
between increasingly distant blood vessel and hypertrophied cells in obese AT.  Hypoxia increases leptin 487 
independently by amongst others an upregulation of HIF1A (35,36). As mentioned above, leptin may 488 
stimulate AT fibrosis by increasing expression of the fibrotic genes SPARC and TGF-beta, the latter as 489 
demonstrated in the peritoneal mesenthelial cells (37).  In contrast to its profibrotic action, leptin has also 490 
been shown to increase expression of the membrane protein Caveolin which in turn impairs leptin signalling 491 
preventing leptin-mediated reduction in lipid accumulation (30).  In line with this, we have shown that at 492 
high doses leptin decreases COL6A3 which may allow free expansion and safe storage of surplus fatty acids.  493 
With its profibrotic and potentially proinflammatory actions, leptin promotes AT dysfunction whilst it also 494 
appears to be able to preserve AT expandability, a contradictory observation. Adding to the complexity is the 495 
potential of peripheral leptin resistance in obesity which may selectively attenuate certain properties but not 496 
others. Further research is required to disentangle in which tissue leptin takes on specific roles as it may have 497 
similar characteristics to SPARC which is multifunctional and its function dependent on cellular 498 
environment and tissue type (38). 499 
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 500 
In conclusion, we have demonstrated that in humans, unlike rodents, COL6A3 expression does not correlate 501 
with impaired metabolic health, does not respond to variations in insulin but conversely decreased with 502 
obesity.  The observation that COL6A3 expression levels increase following weight loss, coupled with our 503 
data highlighting the direct repression of COL6A3 following leptin treatment, suggest the presence of a 504 
potential paracrine regulatory mechanism in which leptin is able to modulate levels of this pericellular 505 
collagen to regulate ECM remodelling. This confirms previous observations of leptin as a potent modulator 506 
of the ECM in human AT. 507 
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Figure Legends 651 
Figure 1. COL6A3 expression and adipose tissue distribution.  (A) Omental AT (OMAT) biopsies from 652 
six female subjects were digested and COL6A3 expression determined in cells of the SVF (black bars) and 653 
adipocytes (grey bars).  COL6A3 mRNA expression levels were determined in paired subcutaneous AT 654 
(SCAT) and OMAT biopsies taken from female subjects undergoing gynaecological surgery (n=19) (B) and 655 
from subjects undergoing bariatric surgery (n=11) (C).  Expression was measured in the SCAT (black bars) 656 
and OMAT samples (grey bars) and group means compared. (D) COL6A3 mRNA expression levels were 657 
determined in lean (black bars) and obese (grey bars) subjects matched for age, gender and ethnicity.  658 
COL6A3 mRNA expression levels were determined in SCAT (n=11 pairs, lean vs obese) and OMAT (n=13 659 
pairs, lean vs obese).  Expression is presented as mean±SEM (AU) and statistical significance determined 660 
using Wilcoxon signed rank test, * p<0.05, **p<0.01. 661 
Figure 2. COL6A3 expression following weight gain and weight loss.  (A) COL6A3 expression was 662 
determined in SCAT of six subjects before and four weeks post (W4) exposure to hyperalimentation in the 663 
fast food study (FFS, black squares), and dieting at baseline and week 16 (W16) of a VLCD (n=24).  An 664 
additional biopsy was taken at week 18 (W18) following two weeks of refeeding (black circles).  Data are 665 
presented in Signal Intensity Units.  Black horizontal bars represent mean expression. (B-H)SCAT biopsies 666 
and serum samples were obtained from subjects during and post bariatric surgery. (B) COL6A3 expression 667 
was determined in SCAT biopsies (n=11) before and after surgery.  COL6A3 expression in paired adipocytes 668 
(C) and SVF (D) after bariatric surgery (n=5), different lines indicate the paired adipocyte and SVF samples.  669 
COL6A3 levels were also determined in the serum of subjects pre and post surgery (E).  COL6A3 expression 670 
and BMI correlation (F). (G) Circulating leptin changes after surgery. Leptin (ng/ml) decreased post-671 
surgically as determined using ELISA’s (n=9). (H) COL6A3 expression was correlated to serum leptin.  Data 672 
are presented as mean±SEM, *p<0.05, **p<0.01. 673 
Figure 3.  AT COL expression following 24 hour culture with recombinant leptin.  SCAT biopsies from 674 
nine female subjects were processed to explants and treated with recombinant leptin (0.1nM, 10nM and 675 
100nM) for 24 hours.  Expression levels of COL6A3 (A) and other collagens (B-E) were determined using a 676 
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Friedman One-way ANOVA with a post-hoc Dunn test comparing to control samples.  Expression levels are 677 
provided as mean±SEM in Arbitrary Units (AU). *p<0.05, **p<0.01.   678 
Figure 4.  ECM collagen distribution. (A) Comparative collagen expression in metabolically relevant 679 
tissues.  Tissue biopsies were obtained from 11 subjects undergoing bariatric surgery.  Expression levels of 680 
COL1A1 (black), COL3A1 (grey), COL4A1 (black squares), COL5A3 (white) and COL6A3 (black diagonal 681 
stripes) were determined following normalisation to four endogenous controls (PPIA, UBC, PGK1 and 682 
GAPDH).  All expression levels are relative to COL1A1 expression within the respective tissue.  683 
Immunostaining of COL6A3 in human omental adipose tissue. Immunohistochemical staining to detect 684 
COL6A3.  Representative microphotographs showing collagen VI (brown) staining in extracellular spaces of 685 
omental adipose tissue (B) and testis (positive control, (C). Negative control showing omental adipose tissue 686 
processed without primary antibody (D).  Nuclei were counterstained with DAPI (blue). Magnification 687 
(400x), scale bar = 2µM. 688 
Figure 5.  Leptin’s regulation of fat mass in the development of obesity and relevant feedback loops. 689 
Leptin levels increase in relation to fat mass and is upregulated by hypoxia. It controls fat mass by several 690 
mechanisms including centrally by a reduction of appetite. In AT it acts in a paracrine/autocrine manner, it is 691 
decreasing fat mass by promoting lipolysis and may predispose to fibrosis by increasing SPARC and 692 
TGFbeta. This may in part attribute to leptin resistance as marked by the dotted line. Less understood are 693 
pathways by which it aids healthy fat expansion furthered by an increase in Caveolin1 and reduction in 694 
COL6A3. 695 
 696 
 697 
 698 
Table 1. Clinical characteristics of subjects pre and post bariatric surgery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are means ± SD. *p<0.05, **p< 0.01. 
 
Parameters Pre Surgery Post Surgery 
Population 11 11 
Gender (M/F) (3/8) 
Age at surgery (years) 46.3±8.1 
BMI (kg/m
2
) 44.4±7.3 35.9±6.6** 
Weight (kg) 129.3±27.8 103.2±22.5** 
Systolic pressure (mmHg) 129±15.8 120±11.3 
Diastolic pressure (mmHg) 86±10.7 81±7.1 
Diabetes (%) 6(55%) 3(27%) 
% Body fat 49±6.5 42.8±10.6* 
% Lean mass 51.0±6.5 57.5±10.1* 
Past smokers (%) 6(55%) 3(27%) 
Current smokers (%) 1 (9%) 3 (27%) 
Time since operation (months) N/A 9.5±1.1 
Fasting glucose (mmol/L)  5.3±0.8  4.7±0.5* 
Fasting Insulin (mU/L)  19.9±8.0 10.9±4.3** 
HbA1c (mmol/L) (range) 34-54 32-47* 
HOMA-IR 4.7±1.9 2.3±1.0** 
Triglycerides (mmol/L)  1.4±0.6  1.4±0.7 
Total cholesterol (mmol/L)  4.3±1.0  4.8±1.0 
Total cholesterol/HDL  30.8±0.9  3.6±0.9 
ALT (IU/L) 29.1±10.6  24.7±16.9 
Table 1
Click here to download Table: revTable 1.docx 
Table 2.  Clinical characteristic of subjects undergoing dietary intervention studies. 
Parameters VLCD Study FF Study 
 Baseline 8 weeks 16 weeks 18 weeks Baseline Week 4 
Weight (kg)
1
 119±20 101±17 91±16*** 91±16*** 64.2±9.3 71.5±13.0** 
BMI (kg/m
2
)
2
 37.6±4.9 31.8±4.1 28.6±4.1*** 28.9±3.9*** 21.4±2.5 23.7±3.3** 
Waist (cm)
1
 123±12 110±12 101±13*** 101±13***   
Fasting 
glucose 
(mmol/l)
2
 
6.0±1.6 4.5±0.7 4.5±0.7*** 5.0±1.0*** 5.15±0.72 5.8±0.77 
Fasting 
insulin 
(mU/l)
2
 
16±7.4 7.0±4.1 4.3±2.2*** 6.3±3.7*** 4.2±2.7 8.8±2.9* 
HOMA-IR
2
 4.4±2.7 1.4±0.9 0.9±0.5 1.5±1.3*** 0.7±0.5 1.63±0.5* 
HbA1c (%) 4.9±0.9 4.3±0.5 4.2±0.4 4.2±0.4   
SCAT area 
(cm
2
)
3
 
526±166  311±137**    
VAT area 
(cm
2
)
3
 
241±76  101±48**    
Systolic blood 
pressure 
(mmHg)
3
 
138±17 121±12 117±14*** 124±16*** 115±5 125±14 
Table 2
Click here to download Table: revTable 2.docx 
The table shows subjects undergoing a very low calorie diet (VLCD) (n=24) or hyperalimentation by 
a fast food (FF) diet (n=6). Computed tomography was performed at weeks 0 and 16 for adipose 
tissue area calculations in the VLCD study.  Data are presented as means ± SD, *p < 0.05, **p < 
0.01,***p < 0.001 when comparing baseline week 0 with week 16, or week 18 in the VLCD study 
and with week 4 in the FF study.  Data taken from 
1
 (12), 
2
 (11), 
3
(8), 
4
(10). 
Serum leptin
3
 
(ng/ml) 
38.4±19 9.8±7.5 6.3±5.9 8.8±6.7*** 6.4±10.9 14.8±17.7* 
Serum 
adiponectin
3
 
(ng/ml) 
9.0±5.3 11.5±7.3 13.6±6.4 15.2±7.9***   
CRP (mg/l)
4
 5.3±5.8 4.6±5.4 2.4±1.5* 2.4±2.2*   
Table 3.  Association analysis between COL6A3 and anthropometric variables and metabolic 
parameters during diet-induced weight loss 
Predictor Variable Estimate P value 
Leptin mRNA expression -0.2075 <0.0001 
Serum Leptin -0.1098 0.0015 
Adiponectin mRNA expression 0.0040 0.9717 
Serum Adiponectin 0.0733 0.5339 
HOMA-IR -0.1347 0.0047 
HbA1c -0.7346 0.0167 
BMI -0.6087 0.0451 
 
The model assumes that the relation (slope) between the given trait or parameter and the mRNA level 
is constant at all four study visits (weeks 0, 8, 16, 18), yet allows for week specific levels of mRNA.  
The table shows the estimated slopes together with the p-value from the tests for whether the slope 
of these four parallel lines is equal to zero (null hypothesis). 
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